Zepbound

What is Zepbound?

Zepbound is a prescription injectable medication containing tirzepatide, the same active ingredient as Mounjaro, formulated specifically for chronic weight management rather than diabetes. Manufactured by Eli Lilly and Company, Zepbound received FDA approval on November 8, 2023, under new drug application number 215959 for adults with obesity or overweight with at least one weight-related comorbidity. In December 2024, the FDA expanded the label to include a second indication — treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — making Zepbound the first medication ever approved for OSA. Like Mounjaro, Zepbound activates both GIP and GLP-1 receptors, producing greater weight loss than any single-pathway GLP-1 agonist. The SURMOUNT clinical trial program demonstrated mean weight loss of 22.5 percent of body weight over 72 weeks, and the SURMOUNT-5 head-to-head trial showed Zepbound outperforming Wegovy for total weight loss. Zepbound is administered as a once-weekly subcutaneous injection at doses ranging from 2.5 mg to 15 mg.

How Zepbound works

Zepbound works by simultaneously activating two incretin receptors — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 — which are naturally released by the gut after meals. GLP-1 signals reduce appetite, improve insulin response, slow gastric emptying, and increase feelings of satiety. GIP adds complementary effects on fat metabolism and amplifies the appetite-suppressing signals in the brain. Activating both receptors produces a larger coordinated reduction in caloric intake and a more favorable shift in body composition than single GLP-1 agents. In clinical trials, patients on Zepbound report reduced hunger between meals, smaller voluntary portions, and a diminished pleasure response to high-calorie foods. Tirzepatide has a half-life of approximately five days, supporting once-weekly dosing with steady-state concentrations reached after four to five weeks at any given dose step. The dual mechanism is why Zepbound has produced the largest mean weight-loss figures of any FDA-approved weight-management medication to date. Tirzepatide appears to shift body composition favorably during weight loss, with a higher proportion of fat-mass loss relative to lean-mass loss compared with GLP-1-only agents.

Who Zepbound is for

Zepbound is FDA-approved for two distinct patient populations:

• Adults with obesity (BMI ≥ 30 kg/m²) — as an adjunct to reduced-calorie diet and increased physical activity.
• Adults with overweight (BMI ≥ 27 kg/m²) who also have at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.
• Adults with moderate-to-severe obstructive sleep apnea and obesity — based on the SURMOUNT-OSA trial (approved December 2024). This indication is unique among weight-management medications.

Before prescribing Zepbound, your clinician will evaluate BMI, comorbidities, previous weight-management attempts, kidney function, history of pancreatitis or gallbladder disease, any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and insurance coverage. Zepbound is not approved for type 2 diabetes on its own (Mounjaro is the tirzepatide product for diabetes), use during pregnancy or breastfeeding, or pediatric patients under 18. Insurance coverage for Zepbound is more restrictive than for Mounjaro — many commercial plans and most Medicare Part D plans exclude weight-loss drugs, though the OSA indication has opened coverage for some patients with sleep-related breathing disorders.

How to take Zepbound

Zepbound is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day, with or without food. The injection site is the abdomen, thigh, or upper arm, and patients should rotate sites between doses to prevent skin changes from repeated injections at the same location. Each Zepbound pen is a pre-filled, single-dose auto-injector — never reuse or share.

The titration schedule begins at 2.5 mg weekly for four weeks as a starter dose, meant to let the body adjust and reduce early gastrointestinal side effects. After four weeks, the dose increases to 5 mg weekly, which is the first effective maintenance dose for weight loss. Prescribers may increase the dose by 2.5 mg increments every four weeks as needed — 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg — until the patient reaches their target weight-loss rate or tolerability limit. The maximum approved dose is 15 mg weekly. Not every patient needs to reach the maximum; prescribers often stop titrating once adequate weight loss is underway.

If you miss a dose and the next scheduled dose is more than four days away, take the missed dose as soon as you remember. If the next dose is three days or less away, skip the missed dose and resume your regular schedule. Do not take two doses within a four-day window. Store unopened pens in the refrigerator between 36°F and 46°F (2-8°C). Pens can stay at room temperature (up to 86°F / 30°C) for up to 21 days before being discarded.

Side effects of Zepbound

Side effects with Zepbound follow the dose-dependent gastrointestinal pattern typical of incretin medications, with frequency comparable to Mounjaro at matched doses. All frequencies below come from the SURMOUNT clinical trial program pooled data in the FDA prescribing information.

Common side effects (worst during titration, typically improving over 2-3 months):

• Nausea — reported in approximately 29 percent of patients, peaking during dose escalation
• Diarrhea — 23 percent
• Constipation — 17 percent, can persist longer than other GI effects
• Vomiting — 13 percent, more frequent at higher doses
• Abdominal pain — 10 percent
• Injection site reactions — 8 percent, typically minor
• Fatigue — 7 percent
• Dyspepsia, eructation, flatulence — each in the 3 to 6 percent range

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 1 percent) — severe, persistent upper abdominal pain radiating to the back
• Gallbladder disease (cholelithiasis, cholecystitis, approximately 0.6 to 1 percent) — risk elevates with rapid weight loss
• Acute kidney injury — secondary to dehydration from persistent GI effects
• Hypoglycemia — rare with Zepbound alone; rises when combined with insulin or sulfonylureas in the small subset of patients with concurrent type 2 diabetes
• Diabetic retinopathy complications — documented in Mounjaro trials; rapid glycemic improvement may temporarily worsen retinopathy in affected patients
• Serious allergic reactions — anaphylaxis and angioedema reported post-marketing

Management strategies — slow titration, eat smaller meals more frequently, avoid high-fat or very spicy foods during dose increases, maintain hydration, limit alcohol during first weeks at each new dose. Contact your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, chest pain, or any rapidly evolving symptom. For patients on Zepbound during active weight loss, preventing muscle loss with resistance training and adequate protein is also worth discussing with your prescriber.

Who should not take Zepbound

Zepbound is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to tirzepatide or any Zepbound excipient
• Concurrent use of other GLP-1 or dual incretin receptor agonists

Boxed warning: Tirzepatide caused thyroid C-cell tumors in rodent studies. The human relevance has not been determined. Patients should report any persistent neck mass, dysphagia, dyspnea, or hoarseness to their prescriber.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastroparesis or other significant gastrointestinal motility disorder, significant kidney impairment (volume depletion from GI effects can worsen renal function), pre-existing diabetic retinopathy, pregnancy or plans to become pregnant (discontinue before pregnancy due to the five-day half-life), or breastfeeding. Because Zepbound slows gastric emptying, the absorption of orally administered medications may be affected — especially oral contraceptives, thyroid hormone, warfarin, and time-critical cardiovascular drugs. The oral contraceptive interaction is particularly important — women using oral contraceptives should switch to a non-oral method or add a barrier method during initiation and for four weeks after each dose escalation. Concurrent use with other GLP-1 or dual incretin receptor agonists (Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, Victoza, Saxenda, Byetta, Bydureon, Foundayo) is not recommended.

What to expect on Zepbound

Zepbound's weight-loss trajectory is steeper than other approved agents, but the curve is still gradual — expect months, not weeks, to see substantial changes.

Week 1 to week 16 (titration through 10 mg). Appetite suppression builds noticeably with each dose increase. By week 4 patients often report feeling fuller faster. By week 12 many describe not thinking about food between meals. GI side effects peak in the first 3 to 7 days after each dose step and subside as the body adapts. Weight loss averages 5 to 8 kg during this phase.

Week 17 to month 9 (maintenance at 10 to 15 mg). This is the period of steepest weight loss. In SURMOUNT-1, patients on Zepbound 15 mg weekly lost an average of 11 percent of body weight by month 6 and continued losing through month 18. Blood pressure typically drops, lipid profiles improve, and many patients with prediabetes see normalization of fasting glucose.

Month 9 to month 18. Weight loss continues to accumulate at a decelerating rate. At 72 weeks in SURMOUNT-1, mean weight loss was 22.5 percent of body weight on the 15 mg dose (25.3 kg absolute); roughly 63 percent of treated patients lost 20 percent or more. In the SURMOUNT-5 head-to-head trial against Wegovy 2.4 mg, Zepbound 15 mg produced superior total weight loss.

Beyond 18 months and long-term. Patients who continue Zepbound at their maintenance dose typically sustain or modestly extend their weight loss. Patients who discontinue regain a majority of the lost weight within one to two years, paralleling the pattern seen with semaglutide-based agents. Your prescriber will schedule follow-up every three to six months to monitor weight, cardiometabolic labs, sleep symptoms if relevant, and tolerability. The SURPASS-CVOT trial (for the same active ingredient via Mounjaro) is expected to report cardiovascular outcomes in 2025.

Zepbound cost and coverage

The list price of Zepbound is approximately $1,086 per four-pen pack before insurance, based on the Eli Lilly wholesale acquisition cost. There is no FDA-approved generic version, and Lilly holds patent protection blocking generic competition until at least 2036.

What you actually pay depends heavily on coverage, and Zepbound coverage is significantly more restrictive than Mounjaro:

• Commercial insurance for obesity: Some plans cover Zepbound for patients with a documented obesity diagnosis, usually with prior authorization and sometimes step-therapy rules. Copays commonly range from $25 to $300 per month. Many plans exclude weight-loss drugs entirely.
• Commercial insurance for OSA: The December 2024 OSA indication has begun to open coverage for patients with documented moderate-to-severe obstructive sleep apnea and obesity, under medical or sleep-disorder benefits rather than weight-loss exclusions.
• Medicare Part D: Currently does not cover Zepbound when prescribed for weight loss alone under current federal law. Coverage for the OSA indication is emerging and plan-dependent.
• Medicaid: Coverage varies dramatically by state; some states cover Zepbound for obesity while most exclude it.
• Manufacturer savings: The Lilly Zepbound Savings Card can reduce eligible commercially-insured patients' copay to as low as $25 per month for up to 12 prescriptions; not available to Medicare or Medicaid beneficiaries.
• LillyDirect: Eli Lilly's direct-to-consumer pharmacy offers self-pay pricing for Zepbound vials at reduced cost (approximately $349 to $699 per month depending on dose and supply option), bypassing traditional insurance. The vials are a different presentation from the single-use pens and require manual drawing with a syringe.

Check your specific plan's coverage, prior-authorization rules, and the current Lilly savings program before filling — weight-management drug coverage terms change more frequently than most medications.